Clinical Trial

Individualizing Anti-TNF Therapy in Patients With Inflammatory Bowel Disease

Recruiting
View on ClinicalTrials.gov →
Summary
This observational study aims to identify genes that may affect how patients with inflammatory bowel disease respond to anti-TNF treatment and why some patients lose response to treatment over time. The study will examine whether genetic markers can help predict which patients are more likely to respond to anti-TNF therapy. Participants who have not previously received anti-TNF treatment and are about to start advanced therapy will provide a blood sample to test for the genetic markers. Participants will also undergo regular assessments of current treatment, disease activity, and inflammatory markers during follow-up.
Trial Details
NCT Number NCT07644117
Lead Sponsor Shmuel Kivity, MD
Conditions IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)
Enrollment 40 participants
Start Date 2025-01-04
Primary Completion 2028-05 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12